U.S. market Closed. Opens in 9 hours 56 minutes

CRBP | Corbus Pharmaceuticals Holdings, Inc. Stock Overview

(Stock Exchange: NASDAQ)
Day's Range 17.20 - 19.37
52 Week Range 3.03 - 61.90
Beta 2.79
Implied Volatility 96.97%
IV Rank 16.35%
Day's Volume 537,335
Average Volume 647,154
Shares Outstanding 12,043,900
Market Cap 220,523,809
Sector Healthcare
Industry Biotechnology
IPO Date 2014-10-27
Valuation
Profitability
Growth
Health
P/E Ratio -3.16
Forward P/E Ratio N/A
EPS -5.79
1YR Price Target N/A
Dividend Yield N/A
Dividend Per Share N/A
Dividend ExDate N/A
Dividend PayDate N/A
Employees 19
Country USA
Website CRBP
Corbus Pharmaceuticals Holdings, Inc., a biopharmaceutical company, focuses on the development of immune modulators for immuno-oncology and fibrosis diseases. It develops lenabasum, an oral molecule that selectively activates cannabinoid receptor type 2 (CB2), which is in Phase II clinical trial to treat systemic lupus erythematosus; CRB-601, an anti-integrin monoclonal antibody (mAb) for the treatment of cancer and fibrosis that inhibits the activation of transforming growth factor ß (TGFß); and CRB-602, an anti-avß6/avß8 mAb that blocks the activation of TGFß for the treatment of fibrotic diseases. The company is also developing cannabinoid receptor type 1 inverse agonist program for the treatment of metabolic disorders, such as obesity, diabetic nephropathy, diabetic retinopathy, and nonalcoholic steatohepatitis; fibrotic diseases, including lung, cardiac, renal disease, and liver fibrosis; and other diseases comprising ascites, cognitive defects, Prader-Willi syndrome, and smoking cessation. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, including the Jenrin library of approximately 600 compounds, and multiple issued and pending patent filings. The company was incorporated in 2009 and is based in Norwood, Massachusetts.
*Chart delayed
Analyzing fundamentals for CRBP we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is very bad and Health is weak. For more detailed analysis please see CRBP Fundamentals page.

Watching at CRBP technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on CRBP Technicals page.
An error has occurred. This application may no longer respond until reloaded. Reload 🗙